Načítá se...
Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness
Rituximab (375 mg/m(2)) achieved remission of the first episode and six relapses of nephrotic syndrome (NS) in a young male patient with podocyte phospholipase A(2) receptor (PLA(2)R)-related membranous nephropathy (MN) refractory to steroids and cyclosporine. Between-treatments interval averaged 17...
Uloženo v:
| Vydáno v: | BMJ Case Rep |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7035801/ https://ncbi.nlm.nih.gov/pubmed/31980477 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2019-232896 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|